Donepezil reduces the time caregivers spend providing care: Results of a one-year, double-blind randomized trial in patients with mild to moderate Alzheimer's disease.

被引：0
|
作者：
Mastey, V
Wimo, A
Winblad, B
Haglund, A
Jacobson, L
Miceli, R
Zhang, R
Subbiah, P
机构：
[1] Pfizer Inc, Pfizer Pharmaceut Grp, New York, NY USA
[2] Umea Univ, Dept Family Med, Umea, Sweden
[3] Karolinska Inst, Huddinge, Sweden
[4] Pfizer AB, Taby, Sweden
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2001年 / 49卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
P16
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [41] Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
    Samuel T Henderson
    Janet L Vogel
    Linda J Barr
    Fiona Garvin
    Julie J Jones
    Lauren C Costantini
    Nutrition & Metabolism, 6
  • [42] Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
    Henderson, Samuel T.
    Vogel, Janet L.
    Barr, Linda J.
    Garvin, Fiona
    Jones, Julie J.
    Costantini, Lauren C.
    NUTRITION & METABOLISM, 2009, 6
  • [43] Effect and Safety of Huannao Yicong Formula in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial
    Yang, Yang
    Liu, Jian-ping
    Fang, Jun-yan
    Wang, Hui-chan
    Wei, Yun
    Cao, Yu
    Liu, Jian-gang
    Liu, Long-tao
    Li, Hao
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2019, 25 (08) : 574 - 581
  • [44] Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
    Gold, Michael
    Alderton, Claire
    Zvartau-Hind, Marina
    Egginton, Sally
    Saunders, Ann M.
    Irizarry, Michael
    Craft, Suzanne
    Landreth, Gary
    Linnamaegi, Uella
    Sawchak, Sharon
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2010, 30 (02) : 131 - 146
  • [45] Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a one-year placebo-controlled study and two-year follow-up study
    Winblad, B
    Wimo, A
    Wetterholm, AL
    Haglund, A
    Engedal, K
    Soininen, H
    Verhey, FRJ
    Waldemar, G
    Zhang, R
    Burger, L
    Schindler, R
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S404 - S404
  • [46] Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a one-year placebo-controlled study and two-year follow-up study
    Winblad, B
    Engedal, K
    Soininen, H
    Waldemar, G
    Verhey, F
    Wimo, A
    Wetterholm, AL
    Haglund, A
    Zhang, R
    Burger, L
    Schindler, R
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 293 - 294
  • [47] A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease (vol 57, pg 613, 2001)
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Subbiah, P
    Whalen, E
    NEUROLOGY, 2001, 57 (11) : 2153 - 2153
  • [48] Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease - Results of a preliminary evaluation
    Friedhoff, L
    Rogers, SL
    NEUROLOGY, 1997, 48 (03) : 2026 - 2026
  • [49] Donepezil: A meta-analysis of individual patient data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease.
    Perdomo, C
    Wilcock, GK
    Whitehead, A
    Evans, JG
    Birks, J
    Pratt, RD
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 197 - 197
  • [50] Donepezil: A meta-analysis of individual patient data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease.
    Pratt, RD
    Wilcock, GK
    Evans, JG
    Birks, J
    Whitehead, A
    Perdomo, CA
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (04) : S19 - S20
12345